Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking an Ionis-partnered candidate that could offer dosing just once a year into pivotal trials on the strength of ...
Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the company has now lined up what looks like an impressive successor. The pharma ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback